BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barkhuizen M, Anderson DG, Grobler AF. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies. Neurochem Int 2016;93:6-25. [PMID: 26743617 DOI: 10.1016/j.neuint.2015.12.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y, Chen X, Li S, Yang X, Qu S, Xu P. The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegener 2016;5:16. [PMID: 27570618 DOI: 10.1186/s40035-016-0063-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
2 Zhang Y, Chen J, Xu C, Feng J, Li J. Effects of glucocerebrosidase gene polymorphisms and mutations on the risk of Parkinson's disease dementia: A meta-analysis. Neurosci Lett 2020;714:134544. [PMID: 31672490 DOI: 10.1016/j.neulet.2019.134544] [Reference Citation Analysis]
3 García-Sanz P, M F G Aerts J, Moratalla R. The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease. Mov Disord 2021;36:1070-85. [PMID: 33219714 DOI: 10.1002/mds.28396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Bhat S, Acharya UR, Hagiwara Y, Dadmehr N, Adeli H. Parkinson's disease: Cause factors, measurable indicators, and early diagnosis. Comput Biol Med 2018;102:234-41. [PMID: 30253869 DOI: 10.1016/j.compbiomed.2018.09.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
5 Pitcairn C, Wani WY, Mazzulli JR. Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. Neurobiol Dis 2019;122:72-82. [PMID: 29550539 DOI: 10.1016/j.nbd.2018.03.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
6 Cilia R, Tunesi S, Marotta G, Cereda E, Siri C, Tesei S, Zecchinelli AL, Canesi M, Mariani CB, Meucci N, Sacilotto G, Zini M, Barichella M, Magnani C, Duga S, Asselta R, Soldà G, Seresini A, Seia M, Pezzoli G, Goldwurm S. Survival and dementia in GBA -associated Parkinson's disease: The mutation matters: Survival in PD- GBA. Ann Neurol 2016;80:662-73. [DOI: 10.1002/ana.24777] [Cited by in Crossref: 162] [Cited by in F6Publishing: 152] [Article Influence: 27.0] [Reference Citation Analysis]
7 Xiong Y, Yu J. Modeling Parkinson's Disease in Drosophila: What Have We Learned for Dominant Traits? Front Neurol 2018;9:228. [PMID: 29686647 DOI: 10.3389/fneur.2018.00228] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
8 Li Q, Jing Y, Lun P, Liu X, Sun P. Association of gender and age at onset with glucocerebrosidase associated Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2021;42:2261-71. [PMID: 33837876 DOI: 10.1007/s10072-021-05230-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci 2017;18:E441. [PMID: 28218669 DOI: 10.3390/ijms18020441] [Cited by in Crossref: 232] [Cited by in F6Publishing: 173] [Article Influence: 46.4] [Reference Citation Analysis]
10 Cerri S, Ghezzi C, Ongari G, Croce S, Avenali M, Zangaglia R, Di Monte DA, Valente EM, Blandini F. GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson's Disease. Int J Mol Sci 2021;22:2215. [PMID: 33672321 DOI: 10.3390/ijms22042215] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cook L, Schulze J. Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings. J Genet Counsel 2017;26:1165-72. [DOI: 10.1007/s10897-017-0123-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Biswas A, Sadhukhan D, Biswas A, Das SK, Banerjee TK, Bal PS, Pal S, Ghosh A, Ray K, Ray J. Identification of GBA mutations among neurodegenerative disease patients from eastern India. Neurosci Lett 2021;751:135816. [PMID: 33711404 DOI: 10.1016/j.neulet.2021.135816] [Reference Citation Analysis]
13 Schneider SA, Alcalay RN. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. J Neurol 2020;267:860-9. [PMID: 31974807 DOI: 10.1007/s00415-020-09705-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
14 Coccia E, Ahfeldt T. Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson's disease. Stem Cell Res Ther 2021;12:253. [PMID: 33926571 DOI: 10.1186/s13287-021-02326-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Creese B, Bell E, Johar I, Francis P, Ballard C, Aarsland D. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. Am J Med Genet 2018;177:232-41. [DOI: 10.1002/ajmg.b.32549] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
16 Stoker TB, Torsney KM, Barker RA; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge, CB2 0PY, UK, Wellcome Trust—Medical Research Council Stem Cell Institute, University of Cambridge, UK, Department of Neurology, Cambridge University Hospitals NHS Foundation Trust; UK, Department of Medicine for the Elderly, Cambridge University Hospitals NHS Foundation Trust, UK, Clinical Gerontology Unit, Department of Public Health and Primary Care, University of Cambridge, UK, John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge, CB2 0PY, UK, Wellcome Trust—Medical Research Council Stem Cell Institute, University of Cambridge, UK, Department of Neurology, Cambridge University Hospitals NHS Foundation Trust; UK. Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018. pp. 45-64. [DOI: 10.15586/codonpublications.parkinsonsdisease.2018.ch3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Jiang Z, Huang Y, Zhang P, Han C, Lu Y, Mo Z, Zhang Z, Li X, Zhao S, Cai F, Huang L, Chen C, Shi Z, Zhang Y, Ling F. Characterization of a pathogenic variant in GBA for Parkinson's disease with mild cognitive impairment patients. Mol Brain 2020;13:102. [PMID: 32641146 DOI: 10.1186/s13041-020-00637-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Dubot P, Astudillo L, Therville N, Sabourdy F, Stirnemann J, Levade T, Andrieu-Abadie N. Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers (Basel) 2020;12:E475. [PMID: 32085512 DOI: 10.3390/cancers12020475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Pará C, Bose P, Pshezhetsky AV. Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression. J Clin Med 2020;9:E616. [PMID: 32106459 DOI: 10.3390/jcm9030616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Riboldi GM, Di Fonzo AB. GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019;8:E364. [PMID: 31010158 DOI: 10.3390/cells8040364] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 19.3] [Reference Citation Analysis]
21 Fiore NJ, Ganat YM, Devkota K, Batorsky R, Lei M, Lee K, Cowen LJ, Croft G, Noggle SA, Nieland TJF, Kaplan DL. Bioengineered models of Parkinson’s disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04047-7] [Reference Citation Analysis]
22 Gentile G, La Cognata V, Cavallaro S. The contribution of CNVs to the most common aging-related neurodegenerative diseases. Aging Clin Exp Res 2021;33:1187-95. [PMID: 32026430 DOI: 10.1007/s40520-020-01485-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
23 Sauerbier A, Aris A, Lim EW, Bhattacharya K, Ray Chaudhuri K. Impact of ethnicity on the natural history of Parkinson disease. Medical Journal of Australia 2018;208:410-4. [DOI: 10.5694/mja17.01074] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
24 Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH. Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chem Rev 2019;119:1221-322. [DOI: 10.1021/acs.chemrev.8b00138] [Cited by in Crossref: 178] [Cited by in F6Publishing: 141] [Article Influence: 44.5] [Reference Citation Analysis]
25 Abul Khair SB, Dhanushkodi NR, Ardah MT, Chen W, Yang Y, Haque ME. Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated α-Synuclein Mutant A53T and Affects Locomotor Activity. Front Neurosci 2018;12:81. [PMID: 29503608 DOI: 10.3389/fnins.2018.00081] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
26 Henderson MX, Sedor S, McGeary I, Cornblath EJ, Peng C, Riddle DM, Li HL, Zhang B, Brown HJ, Olufemi MF, Bassett DS, Trojanowski JQ, Lee VMY. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult. Neuron 2020;105:822-836.e7. [PMID: 31899072 DOI: 10.1016/j.neuron.2019.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
27 Schneider SA, Hizli B, Alcalay RN. Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism. Neurotherapeutics 2020;17:1378-92. [PMID: 32914362 DOI: 10.1007/s13311-020-00920-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Chen Y, Sud N, Hettinghouse A, Liu CJ. Molecular regulations and therapeutic targets of Gaucher disease. Cytokine Growth Factor Rev 2018;41:65-74. [PMID: 29699937 DOI: 10.1016/j.cytogfr.2018.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hu X, Mao C, Fan L, Luo H, Hu Z, Zhang S, Yang Z, Zheng H, Sun H, Fan Y, Yang J, Shi C, Xu Y. Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells. Stem Cells Int 2020;2020:1061470. [PMID: 32256606 DOI: 10.1155/2020/1061470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
30 Navarro-Romero A, Montpeyó M, Martinez-Vicente M. The Emerging Role of the Lysosome in Parkinson's Disease. Cells 2020;9:E2399. [PMID: 33147750 DOI: 10.3390/cells9112399] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Jinnah HA, Albanese A, Bhatia KP, Cardoso F, Da Prat G, de Koning TJ, Espay AJ, Fung V, Garcia-Ruiz PJ, Gershanik O, Jankovic J, Kaji R, Kotschet K, Marras C, Miyasaki JM, Morgante F, Munchau A, Pal PK, Rodriguez Oroz MC, Rodríguez-Violante M, Schöls L, Stamelou M, Tijssen M, Uribe Roca C, de la Cerda A, Gatto EM; International Parkinson's Disease Movement Disorders Society Task Force on Rare Movement Disorders. Treatable inherited rare movement disorders. Mov Disord 2018;33:21-35. [PMID: 28861905 DOI: 10.1002/mds.27140] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
32 Reed X, Schumacher-Schuh A, Hu J, Bandres-Ciga S. Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management. J Pers Med 2021;11:169. [PMID: 33804504 DOI: 10.3390/jpm11030169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Adler CH, Beach TG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Patel A, Sue LI, Serrano G, Jacobson SA, Davis K, Belden CM, Dugger BN, Paciga SA, Winslow AR, Hirst WD, Hentz JG. GBA mutations in Parkinson disease: earlier death but similar neuropathological features. Eur J Neurol 2017;24:1363-8. [PMID: 28834018 DOI: 10.1111/ene.13395] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
34 Nasrolahi A, Safari F, Farhoudi M, Khosravi A, Farajdokht F, Bastaminejad S, Sandoghchian Shotorbani S, Mahmoudi J. Immune system and new avenues in Parkinson’s disease research and treatment. Reviews in the Neurosciences 2019;30:709-27. [DOI: 10.1515/revneuro-2018-0105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
35 Rebiai R, Givogri MI, Gowrishankar S, Cologna SM, Alford ST, Bongarzone ER. Synaptic Function and Dysfunction in Lysosomal Storage Diseases. Front Cell Neurosci 2021;15:619777. [PMID: 33746713 DOI: 10.3389/fncel.2021.619777] [Reference Citation Analysis]
36 Wang XL, Feng ST, Wang YT, Yuan YH, Li ZP, Chen NH, Wang ZZ, Zhang Y. Mitophagy, a Form of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamics of Parkinson's Disease. Cell Mol Neurobiol 2021. [PMID: 33528716 DOI: 10.1007/s10571-021-01039-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Gomez-Inhiesto E, Acaiturri-Ayesta MT, Ustarroz-Aguirre I, Camahuali D, Urtaran-Laresgoiti M, Basabe-Aldecoa M, Nuño-Solinís R, Urizar E. Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies. Parkinsons Dis 2020;2020:9106026. [PMID: 32454967 DOI: 10.1155/2020/9106026] [Reference Citation Analysis]